Cyclooxygenases (COX) act on arachidonic acid to generate prostaglandins. They exist either as COX-1 or COX-2. COX-1, a constitutive enzyme associated with the endoplasmic reticulum, is responsible for maintaining normal physiologic function. It is found throughout the body, especially in the GI tract, kidneys, and platelets and its inhibition by NSAID is reported to cause GI damage, renal dysfunction, and platelet abnormalities. COX-2 is an inducible enzyme that is mainly associated with the nuclear envelope. It′s activity is induced by several growth factors, cytokines, and inflammatory signals. COX-2 expression is markedly increased in 85-90% of human colorectal adenocarcinomas, whereas COX-1 levels remain unchanged. Based on structural differences in the active sites of these isozymes, a new drug has been developed that specifically inhibits only the COX-2 activity. COX-2 inhibitors have the potential to provide the traditional benefits of NSAID with significantly reduced incidence of endoscopic ulcers. Hence, they offer greater therapeutic promise in the treatment of inflammation and cancer. This inhibitor set provides 4 inhibitors for testing the inhibitory effects on COX-1 and COX-2.
Contains 100 mg of Meloxicam, 5 mg of NS-398, 5 mg of SC-560, and 5 mg of Sulindac Sulfide.
